Could cardiovascular disease risk stratification and management in rheumatoid arthritis be enhanced?

Annals of the Rheumatic Diseases

Volumn 72, Issue 11, 2013, Pages 1743-1746

  Dessein, Patrick H ^a   Semb, Anne G ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b DIAKONHJEMMET HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; METHOTREXATE; RHEUMATOID FACTOR;

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; CORONARY ARTERY CALCIUM SCORE; DIABETES MELLITUS; DISEASE DURATION; ECHOGRAPHY; FRAMINGHAM RISK SCORE; HEART PROTECTION; HIGH RISK POPULATION; HUMAN; LIFESTYLE MODIFICATION; MORTALITY; MULTIDETECTOR COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK MANAGEMENT; RISK REDUCTION; SCORING SYSTEM; SOCIAL STATUS; SYSTEMATIC CORONARY RISK EVALUATION SCORE;

CARDIOVASCULAR DISEASE; RHEUMATOID ARTHRITIS; TREATMENT; ULTRASONOGRAPHY;

ALGORITHMS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; HUMANS; RISK ASSESSMENT;

EID: 84885172129     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203911     Document Type: Review

References (42)

1. Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690-7.
2. Meune C, Touze E, Trinquart L, et al. High risk of clinical cardiovascular events in rheumatoid arthritis: levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis 2010;103:253-61.
3. Peters MJL, Symmons DPM, McCarey, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.
4. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2012;223:1-68.
5. Greenland P, Alpert JS, Beller GA, et al. 2010 ACC/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010;56:e50-103.
6. Liao Y, McGee DL, Cooper RS, et al. How generalizable are coronary risk prediction models? Comparison of Framingham and two national cohorts. Am Heart J 1999;137:837-45.
7. Roman MJ, Moeller E, Davis A, et al. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 2006;144:249-56.
8. Kobayashi H, Giles JT, Polak JT, et al. Increased prevalence of carotid artery atherosclerosis in rheumatoid arthritis is artery-specific. J Rheumatol 2010;37:730-9.
9. Aubry MC, Maradit-Kremers H, Reinalda MS, et al. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol 2007;34:937-42.
10. Dessein PH, Joffe BI, Veller MG, et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005;32:435-42.
11. Rollefstad S, Kvien TK, Holme I, et al. Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic. Ann Rheum Dis Published Online First: 22 December 2012. doi:10.1136/annrheumdis- 2012-202789
12. Semb AG, Rollefstad S, Provan SA, et al. Carotid plaque characteristics and disease activity in rheumatoid arthritis. J Rheumatol 2013;40:359-68.
13. Crowson CS, Matteson EL, Roger VL, et al. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol 2012;110:420-4.
14. Dessein PH, Norton GR, Woodiwiss AJ, et al. Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 2007;34:943-51.
15. Solomon DH, Kremer J, Curtis JR, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2012;69:1920-5.
16. Gabriel SE. Heart disease and rheumatoid arthritis: understanding the risks. Ann Rheum Dis 2010;69 (Suppl 1):61-4.
17. Semb AG, Kvien TK, Aastveit AH, et al. Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality Risk (AMORIS) Study. Ann Rheum Dis 2010;69:1996-2001.
18. Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011;70:482-7.
19. Solomon A, Woodiwiss AJ, Abdool-Carrim AT, et al. The carotid artery atherosclerosis burden and its relation to cardiovascular risk factors in black and white Africans with established rheumatoid arthritis: a cross-sectional study. J Rheumatol 2012;39:1798-806.
20. Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011;52:1362-70.
21. Gabriel SE. Heart disease and rheumatoid arthritis: understanding the risks. Ann Rheum Dis 2010;69 (Suppl):i61-4.
22. Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 2011;70:8-14.
23. Crowson CS, Gabriel SE. Towards improving cardiovascular risk management in patients with rheumatoid arthritis: the need for accurate risk assessment. Ann Rheum Dis 2011;70: 719-21.
24. Semb AG, Kvien TK, DeMicco DA, et al. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum 2012;64:2836-46.
25. Corrales A, Parra JA, Gonzalez-Juanatey C, et al. Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2013;72: 1764-70.
26. Corrales A, Gonzalez-Juanatey C, Peiro ME, et al. Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis Published Online First: 16 March 2013. doi:10.1136/annrheumdis-2012-203101
27. Brook RD, Bard RL, Patel S, et al. A negative carotid plaque area test is superior to other noninvasive atherosclerosis studies for reducing the likelihood of having underlying significant coronary artery disease. Arterioscler Thromb Vasc Biol 2006;26: 656-62.
28. Gonzalez-Juanatey C, Llorca J, Martin J, et al. Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum 2009;38:366-71.
29. Evans MR, Escalante A, Battafarano DF, et al. Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis. Arthritis Rheum 2011;63:1211-20.
30. Yiu KH, Mok MY, Wang S, et al. Prognostic role of coronary calcification in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Rheumatol 2012;30:345-50.
31. Johnsen SH, Mathiesen EB. Carotid plaque compared with intima-media thickness as a predictor of coronary and cerebrovascular disease. Curr Cardiol Rep 2009;11:21-7.
32. Mancini GB, Dahlof B, Diez J. Surrogate markers for cardiovascular disease: structural markers. Circulation 2004;109(25 Suppl 1):IV22-30.
33. Makover ME, Ebrahim S. What is the best strategy for reducing deaths from heart disease? PLoS Medicine 2005;2:272-6.
34. Kozera L, Andrews J, Morgan AW. Cardiovascular risk and rheumatoid arthritis-the next step: differentiating true soluble markers of cardiovascular risk from surrogate measures of inflammation. Rheumatology 2011;50:1944-54.
35. Rodriguez-Rodriguez L, Lopez-Mejias R, Garcia-Bermudez M, et al. Genetic markers of cardiovascular disease in rheumatoid arthritis. Mediators Inflamm 2012;2012: 574817.
36. Dessein PH, Norton GR, Woodiwiss AJ, et al. Independent relationship between circulating resistin concentrations and endothelial activation in rheumatoid arthritis. Ann Rheum Dis 2013;72:1586-8.
37. de Lemos JA, McGuire DK. Biomarkers in clinical trials. Can we move from fortune telling to disease profiling? Circulation 2011;124: 663-5.
38. Desai SS, Myles JD, Kaplan MJ. Suboptimal cardiovascular risk factor identification and management in patients with rheumatoid arthritis: a cohort analysis. Arthritis Res Ther 2012; 14:R270.
39. Primdahl J, Clausen J, Horslev-Petersen K. Results from systematic screening for cardiovascular risk in outpatients with rheumatoid arthritis in accordance with the EULAR recommendations. Ann Rheum Dis 2013;72:1771-6.
40. Banga JD, van Dijk JL, van Dis I, et al. NHG-standaard cardiovasculair risicomanagement (eerste herziening). Huisarts Wet 2012;55:14-28.
41. Provan SA, Semb AG, Hisdal J, et al. Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Ann Rheum Dis 2011;70: 812-7.
42. Gonzalez A, Maradit KH, Crowson CS, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007;56:3583-7.